These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9492866)

  • 1. Tacrine. A cause of fatal hepatotoxicity?
    Blackard WG; Sood GK; Crowe DR; Fallon MB
    J Clin Gastroenterol; 1998 Jan; 26(1):57-9. PubMed ID: 9492866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ursodeoxycholic acid and prevention of tacrine-induced hepatotoxicity: a pilot study].
    Salmon L; Montet JC; Oddoze C; Montet AM; Portugal H; Michel BF
    Therapie; 2001; 56(1):29-34. PubMed ID: 11322014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrine: a second look. An outdated drug to be discarded.
    Prescrire Int; 1999 Feb; 8(39):16-8. PubMed ID: 10557569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Convulsive crisis as a possible adverse reaction to the treatment with tacrine in Alzheimer's disease].
    García-Díaz JD; Fraguas C; Garcimartín C
    Med Clin (Barc); 1998 Sep; 111(7):279. PubMed ID: 9789247
    [No Abstract]   [Full Text] [Related]  

  • 5. Tacrine-induced liver damage: an analysis of 19 candidate genes.
    Alfirevic A; Mills T; Carr D; Barratt BJ; Jawaid A; Sherwood J; Smith JC; Tugwood J; Hartkoorn R; Owen A; Park KB; Pirmohamed M
    Pharmacogenet Genomics; 2007 Dec; 17(12):1091-100. PubMed ID: 18004213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience.
    Gracon SI; Knapp MJ; Berghoff WG; Pierce M; DeJong R; Lobbestael SJ; Symons J; Dombey SL; Luscombe FA; Kraemer D
    Alzheimer Dis Assoc Disord; 1998 Jun; 12(2):93-101. PubMed ID: 9651138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerance to tacrine, arterial hypotension and leuko-araiosis in Alzheimer's disease.
    Lebert F; Mouly C; Pasquier F
    Age Ageing; 1998 Sep; 27(5):654. PubMed ID: 12675108
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.
    Watkins PB; Zimmerman HJ; Knapp MJ; Gracon SI; Lewis KW
    JAMA; 1994 Apr; 271(13):992-8. PubMed ID: 8139084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Johns Hopkins Dementia Research Clinic.
    Lyketsos CG; Corazzini K; Steele CD; Kraus MF
    J Neuropsychiatry Clin Neurosci; 1996; 8(1):67-73. PubMed ID: 8845704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic potential of tacrine.
    Kurz A
    J Neural Transm Suppl; 1998; 54():295-9. PubMed ID: 9850938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
    Nordberg A; Svensson AL
    Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Balance sheet of tolerance-efficacy on the use of tacrine in 100 cases of Alzheimer's disease].
    Estadieu MC; Machou C; Berthezène P; Pastor MJ; Angelini B; Bohor M; Bongrand MC; Timon-David P; Gastaut JL; Allain H; Michel BF
    Therapie; 1998; 53(1):67-76. PubMed ID: 9773102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.
    Ahlin A; Junthé T; Hassan M; Nybäck H
    Int Psychogeriatr; 1995; 7(1):75-83. PubMed ID: 7579023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reports from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). The efficacy of Tacrine and the measurement of outcomes of Alzheimer's disease.
    Int J Technol Assess Health Care; 1998; 14(2):398-9. PubMed ID: 9678977
    [No Abstract]   [Full Text] [Related]  

  • 15. Tacrine-NO donor and tacrine-ferulic acid hybrid molecules as new anti-Alzheimer agents: hepatotoxicity and influence on the cytochrome P450 system in comparison to tacrine.
    Lupp A; Appenroth D; Fang L; Decker M; Lehmann J; Fleck C
    Arzneimittelforschung; 2010; 60(5):229-37. PubMed ID: 20533758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
    Gutzmann H; Kühl KP; Hadler D; Rapp MA
    Pharmacopsychiatry; 2002 Jan; 35(1):12-8. PubMed ID: 11819153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tacrine: progress in treatment of Alzheimer's disease?].
    Kurz A; Marquard R; Mösch D
    Z Gerontol Geriatr; 1995; 28(3):163-8. PubMed ID: 7664190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity.
    Simon T; Becquemont L; Mary-Krause M; de Waziers I; Beaune P; Funck-Brentano C; Jaillon P
    Clin Pharmacol Ther; 2000 Apr; 67(4):432-7. PubMed ID: 10801254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Should Alzheimer disease be treated with tacrine? Review of the literature].
    Arsland D; Laake K
    Tidsskr Nor Laegeforen; 1996 Sep; 116(23):2791-4. PubMed ID: 8928167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tacrine].
    Dávila C; Viteri C; de Castro P
    Rev Med Univ Navarra; 1997; 41(1):58-64. PubMed ID: 9527715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.